☆ 4.7 Meeting Abstract

Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

BLOOD (2019)

Journal

BLOOD

Volume 134, Issue -, Pages -

Publisher

AMER SOC HEMATOLOGY

DOI: 10.1182/blood-2019-130362

Keywords

-

Categories

Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial

Courtney D. DiNardo, Andre C. Schuh, Eytan M. Stein, Pau Montesinos, Andrew H. Wei, Stephane de Botton, Amer M. Zeidan, Amir T. Fathi, Hagop M. Kantarjian, John M. Bennett, Mark G. Frattini, Patricia Martin-Regueira, Frederik Lersch, Jing Gong, Maroof Hasan, Paresh Vyas, Hartmut Doehner

Summary: The study evaluated the safety and activity of enasidenib plus azacitidine in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia, showing that the combination therapy significantly improved overall response rates compared to azacitidine monotherapy, which may lead to improved outcomes for these patients.

LANCET ONCOLOGY (2021)

Add to Collection

Article Hematology

Combination of azacitidine and enasidenib enhances leukemic cell differentiation and cooperatively hypomethylates DNA

Kyle J. MacBeth, Vivek S. Chopra, Lin Tang, Bing Zheng, Brian Avanzino, Wendy L. See, Martin Schwickart, Maria E. Figueroa, Lynn Quek, Jorge F. DiMartino

Summary: Combination treatment of azacitidine and enasidenib enhances differentiation in AML cells by reducing DNA methylation more effectively than single agent treatments， especially in patients with IDH2 mutations.

EXPERIMENTAL HEMATOLOGY (2021)

Add to Collection

Letter Oncology

Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML

Sakshi Jasra, Mohammed Kazemi, Nishi Shah, Jiahao Chen, Karen Fehn, Yanhua Wang, Ioannis Mantzaris, Noah Kornblum, Alejandro Sica, LizaMarie Bachier, Mendel Goldfinger, Kira Gritsman, Ira Braunschweig, Ulrich Steidl, Aditi Shastri, Amit Verma

Summary: The FDA approval of Ivosidenib and Enasidenib has introduced new possibilities for the treatment of acute myeloid leukemia (AML) in elderly patients. The successful case of a 60-year-old woman achieving complete response to combination therapy with Azacytidine, Enasidenib, and Venetoclax marks a significant advancement in the treatment of refractory AML.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Article Oncology

Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34+ Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients

Pavla Koralkova, Monika Belickova, David Kundrat, Michaela Dostalova Merkerova, Zdenek Krejcik, Katarina Szikszai, Monika Kaisrlikova, Jitka Vesela, Pavla Vyhlidalova, Jan Stetka, Alzbeta Hlavackova, Jiri Suttnar, Patrik Flodr, Jan Stritesky, Anna Jonasova, Jaroslav Cermak, Vladimir Divoky

Summary: The study sheds light on the molecular network complexity underlying response/resistance to hypomethylating agents in MDS and AML-MRC, suggesting that the metabolic status and transcriptional characteristics of CD34(+) cells may be pivotal factors in predicting patient responses.

CANCERS (2021)

Add to Collection

Article Hematology

Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status

Gail J. Roboz, Farhad Ravandi, Andrew H. Wei, Herve Dombret, Felicitas Thol, Maria Teresa Voso, Andre C. Schuh, Kimmo Porkka, Ignazia La Torre, Barry Skikne, Jianhua Zhong, C. L. Beach, Alberto Risueno, Daniel L. Menezes, Gert Ossenkoppele, Hartmut Dohner

Summary: Maintenance therapy with oral azacitidine improves overall survival and relapse-free survival in acute myeloid leukemia patients, regardless of their measurable residual disease (MRD) status at baseline.

BLOOD (2022)

Add to Collection

Article Hematology

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine

Hartmut Doehner, Andrew H. Wei, Gail J. Roboz, Pau Montesinos, Felicitas R. Thol, Farhad Ravandi, Herve Dombret, Kimmo Porkka, Irwindeep Sandhu, Barry Skikne, Wendy L. See, Manuel Ugidos, Alberto Risueno, Esther T. Chan, Anjan Thakurta, C. L. Beach, Daniel Lopes de Menezes

Summary: The QUAZAR AML-001 trial evaluated the efficacy of oral azacitidine in patients with acute myeloid leukemia, showing improved relapse-free survival and overall survival, particularly in patients with NPM1(mut) and FLT3(mut).

BLOOD (2022)

Add to Collection

Article Oncology

Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE)

Esther Natalie Oliva, Anna Candoni, Prassede Salutari, Giuseppe A. Palumbo, Gianluigi Reda, Giuseppe Ianni, Giovanni Tripepi, Maria Cuzzola, Debora Capelli, Corrado Mammi, Caterina Alati, Maria Concetta Cannata, Pasquale Niscola, Bianca Serio, Pellegrino Musto, Ernesto Vigna, Antonio Volpe, Lorella Maria Antonia Melillo, Maria Teresa Arcadi, Donato Mannina, Maria Elena Zannier, Roberto Latagliata

Summary: Azacitidine (AZA) is a hypomethylating agent used for frontline treatment of acute myeloid leukemia (AML) in patients unfit for intensive chemotherapy. Recent research showed that maintenance therapy with AZA during complete remission improved disease-free survival (DFS) up to 2 and 5 years in AML patients aged >68 years.

CANCERS (2023)

Add to Collection

Article Hematology

Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation

Marius Bill, Madlen Jentzsch, Lara Bischof, Jessica Kohlschmidt, Juliane Grimm, Laura Katharina Schmalbrock, Donata Backhaus, Dominic Brauer, Karoline Goldmann, Georg -Nikolaus Franke, Vladan Vucinic, Dietger Niederwieser, Alice S. Mims, Uwe Platzbecker, Ann-Kathrin Eisfeld, Sebastian Schwind

Summary: Somatic mutations in IDH1 and IDH2 genes are common in AML. The presence of IDH mutations may not significantly impact the prognosis of AML patients consolidated by HSCT, but specific mutation locations (IDH1 R132, IDH2 R140, and IDH2 R172) and mutation dynamics do affect the risk of relapse. IDH2 R140 mutations behave more like clonal hematopoiesis-related aberrations, while IDH1 R132 and IDH2 R172 harbor AML disease-specific features.

BLOOD ADVANCES (2023)

Add to Collection

Article Oncology

Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis

Stephane de Botton, Joseph M. Brandwein, Andrew H. Wei, Arnaud Pigneux, Bruno Quesnel, Xavier Thomas, Ollivier Legrand, Christian Recher, Sylvain Chantepie, Mathilde Hunault-Berger, Nicolas Boissel, Salem A. Nehme, Mark G. Frattini, Alessandra Tosolini, Roland Marion-Gallois, Jixian J. Wang, Chris Cameron, Muhaimen Siddiqui, Brian Hutton, Gary Milkovich, Eytan M. Stein

Summary: The study found that enasidenib significantly prolonged survival compared to standard of care among patients with relapsed/refractory AML and an IDH2 mutation who were ineligible for hematopoietic stem cell transplantation. Further research is needed to validate these findings and evaluate the efficacy of enasidenib for other treatment outcomes.

CANCER MEDICINE (2021)

Add to Collection

Article Oncology

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

Courtney D. DiNardo, Anthony S. Stein, Eytan M. Stein, Amir T. Fathi, Olga Frankfurt, Andre C. Schuh, Hartmut Dohner, Giovanni Martinelli, Prapti A. Patel, Emmanuel Raffoux, Peter Tan, Amer M. Zeidan, Stephane de Botton, Hagop M. Kantarjian, Richard M. Stone, Mark G. Frattini, Frederik Lersch, Jing Gong, Diego A. Gianolio, Vickie Zhang, Aleksandra Franovic, Bin Fan, Meredith Goldwasser, Scott Daigle, Sung Choe, Bin Wu, Thomas Winkler, Paresh Vyas

Summary: The combination therapy of ivosidenib and azacitidine showed promising results in treating IDH1-mutant acute myeloid leukemia, with a well-tolerated safety profile and deep, durable responses observed in patients, especially those achieving complete remission and mIDH1 mutation clearance in bone marrow cells.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Hematology

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

Eytan M. Stein, Courtney D. DiNardo, Amir T. Fathi, Alice S. Mims, Keith W. Pratz, Michael R. Savona, Anthony S. Stein, Richard M. Stone, Eric S. Winer, Christopher S. Seet, Hartmut Doehner, Daniel A. Pollyea, James K. McCloskey, Olatoyosi Odenike, Bob Loewenberg, Gert J. Ossenkoppele, Prapti A. Patel, Mikhail Roshal, Mark G. Frattini, Frederik Lersch, Aleksandra Franovic, Salah Nabhan, Bin Fan, Sung Choe, Hongfang Wang, Bin Wu, Lei Hua, Caroline Almon, Michael Cooper, Hagop M. Kantarjian, Martin S. Tallman

Summary: Ivosidenib and enasidenib, as targeted oral inhibitors, demonstrated good safety and efficacy when combined with intensive chemotherapy in newly diagnosed mIDH1/2 AML patients, achieving end-of-induction complete remission rates of 55% and 47% respectively.

BLOOD (2021)

Add to Collection

Article Hematology

Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study

Jan M. Middeke, Klaus H. Metzeler, Christoph Roellig, Michael Kraemer, Jan-Niklas Eckardt, Sebastian Stasik, Philipp A. Greif, Karsten Spiekermann, Maja Rothenberg-Thurley, Utz Krug, Jan Braess, Alwin Kraemer, Andreas Hochhaus, Tim H. Bruemmendorf, Ralph Naumann, Bjoern Steffen, Hermann Einsele, Markus Schaich, Andreas Burchert, Andreas Neubauer, Dennis Goerlich, Cristina Sauerland, Kerstin Schaefer-Eckart, Christoph Schliemann, Stefan W. Krause, Mathias Haenel, Norbert Frickhofen, Richard Noppeney, Ulrich Kaiser, Martin Kaufmann, Desiree Kunadt, Bernhard Woermann, Katja Sockel, Malte von Bonin, Tobias Herold, Carsten Mueller-Tidow, Uwe Platzbecker, Wolfgang E. Berdel, Hubert Serve, Claudia D. Baldus, Gerhard Ehninger, Johannes Schetelig, Wolfgang Hiddemann, Martin Bornhaeuser, Friedrich Stoelzel, Christian Thiede

Summary: Mutations in the isocitrate dehydrogenase-1 (IDH1) and IDH2 genes are common in acute myeloid leukemia (AML), affecting about 20% of patients. While these mutations do not impact treatment response rates or overall survival, different subtypes of IDH1/2 mutations may have an association with outcomes.

BLOOD ADVANCES (2022)

Add to Collection

Article Hematology

Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trial

Daniel L. Menezes, Wendy L. See, Alberto Risueno, Kao Tai Tsai, Jae K. Lee, Johnny Ma, Rida Khan, Thomas Prebet, Barry Skikne, C. L. Beach, Anjan Thakurta, Anita Gandhi

Summary: Oral azacitidine (Oral-AZA) maintenance therapy improves relapse-free (RFS) and overall survival (OS) for AML patients in remission after intensive chemotherapy (IC). Immune profiling reveals that increased levels of lymphocytes, monocytes, T cells, and CD34+ CD117+ BM cells are prognostic for RFS. Oral-AZA modulates T-cell activity, reverses T-cell exhaustion, and is associated with improved clinical outcomes.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Article Oncology

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial

Farhad Ravandi, Gail J. Roboz, Andrew H. Wei, Hartmut Dohner, Christopher Pocock, Dominik Selleslag, Pau Montesinos, Hamid Sayar, Maurizio Musso, Angela Figuera-Alvarez, Hana Safah, William Tse, Sang Kyun Sohn, Devendra Hiwase, Timothy Chevassut, Francesca Pierdomenico, Ignazia La Torre, Barry Skikne, Rochelle Bailey, Jianhua Zhong, C. L. Beach, Herve Dombret

Summary: Oral azacitidine maintenance therapy has shown favorable safety profile with common gastrointestinal and hematologic adverse events, rarely requiring permanent discontinuation. Prophylaxis with antiemetic agents and regular blood count monitoring are recommended for optimal management and treatment adherence.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Review Oncology

IDH Inhibitors in AML-Promise and Pitfalls

Hannah McMurry, Luke Fletcher, Elie Traer

Summary: Mutations in IDH1 and IDH2 are common in AML, with inhibitors of these mutated genes now approved by the FDA for AML treatment. While IDH inhibitors show efficacy as monotherapy, they demonstrate higher response rates when combined with HMAs. Current and future trials are exploring various combination approaches, such as with standard chemotherapy, maintenance therapy, and venetoclax-based regimens, to optimize outcomes for AML patients with IDH mutations.

CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2021)

Add to Collection

Article Hematology

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial

Stephane de Botton, Pau Montesinos, Andre C. Schuh, Cristina Papayannidis, Paresh Vyas, Andrew H. Wei, Hans Ommen, Sergey Semochkin, Hee-Je Kim, Richard A. Larson, Jaime Koprivnikar, Olga Frankfurt, Felicitas Thol, Joerg Chromik, Jenny Byrne, Arnaud Pigneux, Xavier Thomas, Olga Salamero, Maria Belen Vidriales, Vadim Doronin, Hartmut Doehner, Amir T. Fathi, Eric Laille, Xin Yu, Maroof Hasan, Patricia Martin-Regueira, Courtney D. DiNardo

Summary: This study compared the efficacy of the oral IDH2 inhibitor enasidenib with conventional care regimens (CCR) in older patients with late-stage mutant-IDH2 AML. Enasidenib significantly improved event-free survival, time to treatment failure, overall response rate, hematologic improvement, and transfusion independence compared to CCR. However, there was no significant difference in overall survival, possibly due to early dropout and subsequent AML-directed therapies.

BLOOD (2023)

Add to Collection

Article Hematology

Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia

Catia Simoes, Maria-Carmen Chillon, David Martinez-Cuadron, Maria-Jose Calasanz, Maria-Belen Vridiales, Iria Vazquez, Montserrat Hernandez-Ruano, Benat Ariceta, Paula Aguirre-Ruiz, Leire Burgos, Diego Alignani, Sarai Sarvide, Sara Villar, Ana Alfonso Pierola, Felipe Prosper, Rosa Ayala, Joaquin Martinez-Lopez, Juan Miguel Bergua Burgues, Susana Vives, Jose A. Perez-Simon, Maria Garcia-Fortes, Teresa Bernal del Castillo, Mercedes Colorado, Mayte Olave, Juan I. Rodriguez-Gutierrez, Jorge Labrador, Marcos Gonzalez, Jesus F. San-Miguel, Miguel angel Sanz, Pau Montesinos, Bruno Paiva

Summary: Clonal evolution in acute myeloid leukemia (AML) can be reconstructed using integrated multidimensional flow cytometry (MFC) immunophenotyping and fluorescence-activated cell sorting (FACS) with next-generation sequencing (NGS). Mutational analysis of dysplastic cells and leukemic blasts at the onset of AML identified stable, branching, and clonal evolution patterns. Techniques other than single-cell multiomics can be used to detect measurable residual disease (MRD) and genetic traits associated with treatment resistance in patients achieving complete response (CR). Whole-exome sequencing revealed different clonal involvement in dysplastic myeloerythropoiesis, leukemic transformation, and chemoresistance.

BLOOD ADVANCES (2023)

Add to Collection

Letter Hematology

Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial

Andrew H. Wei, Hartmut Doehner, Hamid Sayar, Farhad Ravandi, Pau Montesinos, Herve Dombret, Dominik Selleslag, Kimmo Porkka, Jun-Ho Jang, Barry Skikne, C. L. Beach, Thomas Prebet, George Zhang, Alberto Risueno, Manuel Ugidos, Wendy L. See, Daniel Menezes, Gail J. Roboz

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Review Pharmacology & Pharmacy

Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape

Antonio Solana-Altabella, Juan Eduardo Megias-Vericat, Octavio Ballesta-Lopez, David Martinez-Cuadron, Pau Montesinos

Summary: This review summarizes the drug-drug interactions (DDIs) of FLT3 inhibitors with various transporters and metabolic pathways. Healthcare professionals should be aware of potential interactions and closely monitor patients receiving drugs that may interact with FLT3 inhibitors.

EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2023)

Add to Collection

Article Hematology

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial

Justin M. Watts, Maria R. Baer, Jay Yang, Thomas Prebet, Sangmin Lee, Gary J. Schiller, Shira N. Dinner, Arnaud Pigneux, Pau Montesinos, Eunice S. Wang, Karen P. Seiter, Andrew H. Wei, Stephane De Botton, Montserrat Arnan, Will Donnellan, Anthony P. Schwarer, Christian Recher, Brian A. Jonas, P. Brent Ferrell Jr, Christophe Marzac, Patrick Kelly, Jennifer Sweeney, Sanjeev Forsyth, Sylvie M. Guichard, Julie Brevard, Patrick Henrick, Hesham Mohamed, Jorge E. Cortes

Summary: This study evaluated the safety, pharmacokinetics, pharmacodynamics, and clinical activity of Olutasidenib in patients with acute myeloid leukemia or myelodysplastic syndrome with mutant IDH1. The results showed that Olutasidenib, as monotherapy or in combination with azacitidine, was well tolerated and exhibited meaningful clinical activity. These findings provide a rationale for further evaluation of Olutasidenib in different populations of patients with myeloid malignancies.

LANCET HAEMATOLOGY (2023)

Add to Collection

Article Oncology

Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry

Claudia Sargas, Rosa Ayala, Maria Jose Larrayoz, Maria Carmen Chillon, Estrella Carrillo-Cruz, Cristina Bilbao-Sieyro, Esther Prados de la Torre, David Martinez-Cuadron, Rebeca Rodriguez-Veiga, Blanca Boluda, Cristina Gil, Teresa Bernal, Juan Miguel Bergua, Lorenzo Algarra, Mar Tormo, Pilar Martinez-Sanchez, Elena Soria, Josefina Serrano, Juan Manuel Alonso-Dominguez, Raimundo Garcia-Boyero, Maria Luz Amigo, Pilar Herrera-Puente, Maria Jose Sayas, Esperanza Lavilla-Rubira, Joaquin Martinez-Lopez, Maria Jose Calasanz, Ramon Garcia-Sanz, Jose Antonio Perez-Simon, Maria Teresa Gomez-Casares, Joaquin Sanchez-Garcia, Eva Barragan, Pau Montesinos

Summary: Next-Generation Sequencing (NGS) has provided a deeper genetic understanding of acute myeloid leukemia (AML) and is becoming an irreplaceable diagnostic tool in clinical settings. The PETHEMA cooperative group has established a nationwide NGS network to study molecular profiles in AML patients, supporting the increasing role of NGS in clinical management.

CANCERS (2023)

Add to Collection

Article Medicine, Research & Experimental

Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia

Friedrich Stoelzel, Sarah E. Fordham, Devi Nandana, Wei-Yu Lin, Helen Blair, Claire Elstob, Hayden L. Bell, Brigitte Mohr, Leo Ruhnke, Desiree Kunadt, Claudia Dill, Daniel Allsop, Rachel Piddock, Emmanouela-Niki Soura, Catherine Park, Mohd Fadly, Thahira Rahman, Abrar Alharbi, Manja Wobus, Heidi Altmann, Christoph Roellig, Lisa Wagenfuehr, Gail L. Jones, Tobias Menne, Graham H. Jackson, Helen J. Marr, Jude Fitzgibbon, Kenan Onel, Manja Meggendorfer, Amber Robinson, Zuzanna Bziuk, Emily Bowes, Olaf Heidenreich, Torsten Haferlach, Sara Villar, Benat Ariceta, Rosa Ayala Diaz, Steven J. Altschuler, Lani F. Wu, Felipe Prosper, Pau Montesinos, Joaquin Martinez-Lopez, Martin Bornhaeuser, James M. Allan

Summary: Precision medicine is important in improving outcomes for cancer patients, and in this study, it was found that elderly patients with acute myeloid leukemia (AML) who had somatic biallelic TET2 mutations were resistant to certain chemotherapies but sensitive to 5'-azacitidine (5'-Aza) hypomethylating monotherapy. Experimental evidence showed that cells with biallelic TET2 mutations were more sensitive to 5'-Aza compared to cells with monoallelic mutations. This study suggests the potential use of hypomethylating agents as a treatment option for chemoresistant AML patients with biallelic TET2 mutations and highlights the importance of considering mutant allele dosage in precision medicine for cancer patients.

JCI INSIGHT (2023)

Add to Collection

Article Hematology

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML

Stephane de Botton, Pierre Fenaux, Karen Yee, Christian Recher, Andrew H. Wei, Pau Montesinos, David C. Taussig, Arnaud Pigneux, Thorsten Braun, Antonio Curti, Carolyn Grove, Brian A. Jonas, Asim Khwaja, Ollivier Legrand, Pierre Peterlin, Montserrat Arnan, William Blum, Daniela Cilloni, Devendra K. Hiwase, Joseph G. Jurcic, Juergen Krauter, Xavier Thomas, Justin M. Watts, Jay Yang, Olga Polyanskaya, Julie Brevard, Jennifer Sweeney, Emma Barrett, Jorge Cortes

Summary: Olutasidenib (FT-2102) is an effective and selective oral inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1). In a pivotal cohort study, olutasidenib monotherapy showed a complete remission (CR) plus CR with partial hematologic recovery (CRh) rate of 35% and an overall response rate of 48% in IDH1 inhibitor-naive patients with mIDH1R132 relapsed/refractory acute myeloid leukemia (AML). The median duration of CR/CRh was 25.9 months, and the median overall survival was 11.6 months. Grade 3 or 4 adverse events included febrile neutropenia, anemia, thrombocytopenia, and neutropenia. Differentiation syndrome adverse events occurred in 14% of patients, with one fatal case reported. Olutasidenib provides a therapeutic advance in this poor-prognostic population of AML patients with mIDH1 R/R. This trial was registered at www.clinicaltrials.gov as #NCT02719574.

BLOOD ADVANCES (2023)

Add to Collection

Letter Hematology

Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols

Pere Barba, Mireia Morgades, Pau Montesinos, Jose Gonzalez-Campos, Anna Torrent, Cristina Gil, Teresa Bernal, Mar Tormo, Santiago Mercadal, Sandra Novoa, Irene Garcia-Cadenas, M. Paz Queipo de Llano, Marta Cervera, Rosa Coll, Arancha Bermudez, M. Luz Amigo, Silvia Monsalvo, Jordi Esteve, Raimundo Garcia-Boyero, Andres Novo, Jesus Maria Hernandez Rivas, Antonia Cladera, Pilar Martinez-Sanchez, Josefina Serrano, Maria Teresa Artola, Beatriz Soria, Eugenia Abella, Ferran Vall-Llovera, Juan Bergua, Pilar Herrera, Daniel Barrios, Josep Maria Ribera

HEMASPHERE (2023)

Add to Collection

Article Oncology

A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia

Pau Montesinos, Vamsi Kota, Joseph Brandwein, Pierre Bousset, Rebecca J. Benner, Erik Vandendries, Ying Chen, Mary Frances McMullin

Summary: This study aimed to evaluate the effects of fractionated dosing of gemtuzumab ozogamicin (GO) on the QT interval, pharmacokinetics (PK), and immunogenicity in patients with relapsed/refractory acute myeloid leukemia (AML). The results showed that fractionated dosing of GO is not associated with a clinically significant risk of QT interval prolongation in AML patients, and the presence of antidrug antibodies (ADAs) is not related to potential safety issues.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2023)

Add to Collection

Article Hematology

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial

Sylvie D. Freeman, Abin Thomas, Ian Thomas, Robert K. Hills, Paresh Vyas, Amanda Gilkes, Marlen Metzner, Niels Asger Jakobsen, Alison Kennedy, Rachel Moore, Nuria Marquez Almuina, Sarah Burns, Sophie King, Georgia Andrew, Kathleen M. E. Gallagher, Rob S. Sellar, Paul Cahalin, Duruta Weber, Mike Dennis, Priyanka Mehta, Steven Knapper, Nigel H. Russell

Summary: Addition of gemtuzumab ozogamicin to induction chemotherapy improves outcomes in older AML patients, especially those with MRD<0.1% and IDH mutations. The survival advantage from this treatment is dependent on allogeneic transplantation.

BLOOD (2023)

Add to Collection

Article Hematology

Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain

Anna Torrent, Mireia Morgades, Olga Garcia-Calduch, Maria Paz Queipo de Llano, Pau Montesinos, Irene Navarro, Jesus Maria Hernandez-Rivas, Abelardo Barez-Garcia, Jose Gonzalez-Campos, Itziar Oiartzabal, Marta Valero, Marta Cervera, Teresa Zudaire, Manuel Albors-Ferreiro, Oriana Lopez-Godino, Cristina Gil-Cortes, Lucia Villalon, Raquel Saldana, Josep-Maria Ribera

Summary: This study investigated the efficacy of Inotuzumab ozogamicin (IO) in treating relapsed/refractory B cell precursor acute lymphoblastic leukemia (B-ALL) in adult patients. Results showed that after two cycles of IO, 64% of patients achieved complete response. Early use of IO was found to be effective for relapsed/refractory B-ALL patients.

EUROPEAN JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Article Oncology

Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results

Naval G. Daver, Paresh Vyas, Suman Kambhampati, Monzr M. Al Malki, Richard A. Larson, Adam S. Asch, Gabriel Mannis, Wanxing Chai-Ho, Tiffany N. Tanaka, Terrence J. Bradley, Deepa Jeyakumar, Eunice S. Wang, Kendra Sweet, Hagop M. Kantarjian, Guillermo Garcia-Manero, Rami Komrokji, Guan Xing, Giridharan Ramsingh, Camille Renard, Joshua F. Zeidner, David A. Sallman

Summary: Magrolimab combined with azacitidine showed promising efficacy and tolerability in patients with untreated AML ineligible for intensive chemotherapy, including those with TP53 mutations.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Hematology

Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial

Jorge Sierra, Pau Montesinos, Xavier Thomas, Laimonas Griskevicius, Thomas Cluzeau, Denis Caillot, Ollivier Legrand, Clara Minotti, Mario Luppi, Firas Farkas, Bourras-Rezki Bengoudifa, Geralyn Gilotti, Sejla Hodzic, Alessandro Rambaldi, Adriano Venditti

Summary: The pivotal RATIFY study demonstrated that midostaurin combined with standard chemotherapy significantly reduced mortality in adult patients with newly diagnosed FLT3(mut) acute myeloid leukemia. This open-label, multicenter phase 3b trial aimed to further assess the safety and efficacy of midostaurin plus chemotherapy in different age groups. The results showed that the safety and efficacy of midostaurin remained consistent with previous findings regardless of age, sex, or induction regimen.

BLOOD ADVANCES (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.